Donald Scott, PhD
- PROFESSOR | Medicine, Endocrinology, Diabetes and Bone Disease
Research Topics:
Cancer, Cell Biology, Cell Cycle, Chromatin, Diabetes, Epigenetics, Gene Expressions, Gene Regulation, Gene Therapy, Growth Factors and Receptors, Hormones, Image Analysis, Imaging, Insulin, Insulin Receptor, Knockout Mice, Liver, Molecular Biology, Nucleus, Obesity, Oncogenes, Protein Kinases, RNA, RNA Splicing & Processing, Transcription Factors, Transcriptional Activation and Repression, Transgenic Mice
Donald Scott, PhD, is a Professor in the Division of Endocrinology, Diabetes and Bone Disease. Dr. Scott’s group works on the nutritional regulation of cellular phenotype. The Scott Laboratory works on molecular mechanisms that coordinate how nutrients, especially glucose, alter the regulation of genes to change the phenotype of cells. His work focuses on two glucose-sensing transcription factors, ChREBP and c-Myc. He found that ChREBP activity requires the presence of c-Myc and is currently working out the molecular mechanisms of this relationship. In addition, his lab, in collaboration with colleagues from the Metabolism Institute (Drs. Garcia-Ocaña, Vasavada, and Stewart) found that ChREBP is required for glucose-stimulated beta cell proliferation. This work is funded by the NIH, the American Diabetes Association, and the Juvenile Diabetes Research Foundation.
Dr. Scott is member of the Graduate Faculty and is affiliated with the Systems Biology of Disease and Therapeutics Multiple Training Area.Multi-Disciplinary Training Area
Pharmacology and Therapeutics Discovery [PTD]Education
AB, University of Missouri
MA, University of Missouri
PhD, Saint Louis University
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Scott did not report having any of the following types of financial relationships with industry during 2019 and/or 2020: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.